BMC Cancer · 2015 · 121 citations · 41 references
MedicineImmunologyOncologyCancer ImmunologyInflammationTumor ImmunologyCancer Survival AnalysisImmuno-oncology BiomarkersNeutrophil BiologyTumor ImmunopathologyDisease-free Survival AnalysisDisease-free Survival AssessmentHazard Ratio ModelingImmune Biomarkers In CancerKaplan-meier Confidence IntervalsNeutrophil-to-lymphocyte RatioPre-treatmentSystemic Inflammation Markers
BACKGROUND: There is a growing body of evidence that immune response plays a large role in cancer outcome. The neutrophil to lymphocyte ratio (NLR) has been used as a simple parameter of systemic inflammation in several tumors. The purpose was to investigate the association between pre-treatment NLR, disease-free survival and overall survival in patients with early triple negative breast cancer (TNBC). METHODS: We reviewed the records of patients with stage I-III TNBC at our Institution from 2006 to 2012. The association between pre-treatment NLR and survival was analyzed. The difference among variables was calculated by chi-square test. DFS and OS were estimated using Kaplan-Meier method. Cox analysis was performed to analyze clinical parameters for their prognostic relevance. RESULTS: A total of 90 patients were eligible. There was no significant correlation among pre-treatment NLR and various clinical pathological factors. Patients with NLR higher than 3 showed significantly lower DFS (p = 0.002) and OS (p = 0.009) than patients with NLR equal or lower than 3. The Cox proportional multivariate hazard model revealed that higher pre-treatment NLR was independently correlated with poor DFS and OS, with hazard ratio 5.15 (95% confidence interval [CI] 1.11-23.88, p = 0.03) and 6.16 (95% CI 1.54-24.66, p = 0.01) respectively. CONCLUSION: Our study suggests that pre-treatment NLR may be associated with DFS and OS patients with early TNBC. Further validation and a feasibility study are required before it can be considered for clinical use.
41
Gene expression profiling predicts clinical outcome of breast cancer
Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
Tumor-Infiltrating CD8<sup>+</sup>Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar Mahmoud, Emma C. Paish, Desmond G. Powe et al. · Journal of Clinical Oncology · 2011 · 1.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Sherene Loi, Stefan Michiels, Roberto Salgado et al. · Annals of Oncology · 2014 · 1.3K citations
Medicine, Immunology, Oncology +15